

Cytokinetics Contemporary Forum:

# Novel Care Models to Improve Value and Address Disparities in Heart Failure

Sixth Annual Event

**Saturday, September 11th**

7:00am – 8:00am MT, Colorado A, Gaylord Rockies

Live Stream and OnDemand

Breakfast will be served



## Agenda

7:00 – 7:05 am	<i>Introduction and Program Overview</i>	<b>Ileana L. Piña, Chair</b>
7:05 – 7:20 am	<i>Heart Failure Burden &amp; Disparities in Heart Failure Management: Where are we in 2021?</i>	<b>Nasrien E. Ibrahim</b>
7:20 – 7:35 am	<i>Realizing Value-Based Heart Failure Care: Where We Are and Where We Are Heading</i>	<b>Nihar R. Desai</b>
7:35 – 7:50 am	<i>Partnering in the Care of High Risk Patients with Heart Failure</i>	<b>Robert J. Mentz</b>
7:50 – 7:55 am	<i>Q &amp; A</i>	<b>All Faculty</b>
7:55 – 8:00 am	<i>Closing Remarks and Adjournment</i>	<b>Ileana L. Piña</b>

## Faculty



**Ileana L. Piña MD, MPH, FAHA, FACC, Chair**  
Professor of Medicine, Wayne State University; Clinical Professor of Medicine, Central Michigan University; Senior Staff Fellow, FDA, CDRH; Central Michigan University, Detroit, Michigan



**Nihar R. Desai MD, MPH**  
Associate Professor of Medicine and Associate Chief of Clinical Operations, Section of Cardiovascular Medicine; Investigator, Center For Outcomes Research and Evaluation; Yale University School of Medicine, New Haven, Connecticut



**Nasrien E. Ibrahim, MD**  
Director, Heart Failure Research; Inova Heart and Vascular Institute; Falls Church, VA



**Robert J. Mentz, MD, HFSA, FACC, FAHA**  
Associate Professor of Medicine; Chief, Heart Failure Section; Associate Program Director, Duke Cardiology Fellowship; Editor-in-Chief, Journal of Cardiac Failure; Duke University Medical Center; Duke Clinical Research Institute

This Industry Contemporary Forum/Workshop is not part of the scientific program as planned by the HFSA Program Committee. This event is neither sponsored by nor endorsed by HFSA. This event does not qualify for continuing education credit.



Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.

WV-MED-00791 © 2021 CYTOKINETICS INC. ALL RIGHTS RESERVED